Rajeev Jashnani
Recent Quotes
"JNJ's canagliflozin and Xarelto could add $2.5B in revenues by 2016."
—
Rajeev Jashnani, UBS Securities
(2/21/13)
more >
"Prescription trends have ramped up for JNJ."
—
Rajeev Jashnani, UBS Securities
(12/17/12)
more >
"MDT's Resolute U.S. share has grown from 10% to 27%."
—
Rajeev Jashnani, UBS Securities
(9/20/12)
more >
"JNJ strongly prefers dividends over share repurchase."
—
Rajeev Jashnani, UBS Securities
(8/20/12)
more >
"We reiterate our Buy rating."
—
Rajeev Jashnani, UBS Securities
(7/12/12)
more >
"Trends for JNJ's Xarelto have ramped up appreciably."
—
Rajeev Jashnani, UBS Securities
(6/25/12)
more >
